• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有足够的试验规模为临床实践提供依据。

Sufficient trial size to inform clinical practice.

作者信息

Manski Charles F, Tetenov Aleksey

机构信息

Department of Economics and Institute for Policy Research, Northwestern University, Evanston, IL 60208;

Department of Economics, University of Bristol, Bristol BS8 1TU, United Kingdom; Collegio Carlo Alberto, Moncalieri (TO) 10024, Italy.

出版信息

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10518-23. doi: 10.1073/pnas.1612174113. Epub 2016 Sep 6.

DOI:10.1073/pnas.1612174113
PMID:27601679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5035895/
Abstract

Medical research has evolved conventions for choosing sample size in randomized clinical trials that rest on the theory of hypothesis testing. Bayesian statisticians have argued that trials should be designed to maximize subjective expected utility in settings of clinical interest. This perspective is compelling given a credible prior distribution on treatment response, but there is rarely consensus on what the subjective prior beliefs should be. We use Wald's frequentist statistical decision theory to study design of trials under ambiguity. We show that ε-optimal rules exist when trials have large enough sample size. An ε-optimal rule has expected welfare within ε of the welfare of the best treatment in every state of nature. Equivalently, it has maximum regret no larger than ε We consider trials that draw predetermined numbers of subjects at random within groups stratified by covariates and treatments. We report exact results for the special case of two treatments and binary outcomes. We give simple sufficient conditions on sample sizes that ensure existence of ε-optimal treatment rules when there are multiple treatments and outcomes are bounded. These conditions are obtained by application of Hoeffding large deviations inequalities to evaluate the performance of empirical success rules.

摘要

医学研究已经形成了在基于假设检验理论的随机临床试验中选择样本量的惯例。贝叶斯统计学家认为,在临床相关的情况下,试验设计应旨在最大化主观预期效用。鉴于治疗反应有可信的先验分布,这种观点很有说服力,但对于主观先验信念应该是什么,很少能达成共识。我们使用沃尔德的频率主义统计决策理论来研究在模糊性下的试验设计。我们表明,当试验有足够大的样本量时,存在ε - 最优规则。一个ε - 最优规则在每种自然状态下的预期福利与最佳治疗的福利相差不超过ε。等价地,它的最大遗憾不超过ε。我们考虑在按协变量和治疗分层的组内随机抽取预定数量受试者的试验。我们报告了两种治疗和二元结果这一特殊情况的精确结果。当有多种治疗且结果有界时,我们给出了样本量的简单充分条件,以确保存在ε - 最优治疗规则。这些条件是通过应用霍夫丁大偏差不等式来评估经验成功规则的性能而得到的。

相似文献

1
Sufficient trial size to inform clinical practice.有足够的试验规模为临床实践提供依据。
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10518-23. doi: 10.1073/pnas.1612174113. Epub 2016 Sep 6.
2
A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.一种行为贝叶斯方法在临床试验中用于确定考虑疗效和安全性的样本量:处理组中不平衡的样本量。
Stat Methods Med Res. 2011 Aug;20(4):389-400. doi: 10.1177/0962280209358131. Epub 2010 Mar 11.
3
Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.从工业角度使用信息价值方法确定多阶段适应性随机临床试验的最佳样本量。
Clin Trials. 2013 Feb;10(1):54-62. doi: 10.1177/1740774512467404. Epub 2012 Dec 21.
4
Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.II期临床试验中具有生存终点的贝叶斯决策序贯分析。
Stat Med. 2009 Apr 30;28(9):1339-52. doi: 10.1002/sim.3544.
5
Improving efficiency in the stepped-wedge trial design via Bayesian modeling with an informative prior for the time effects.通过贝叶斯建模,利用时间效应的信息先验,提高阶式楔形试验设计的效率。
Clin Trials. 2021 Jun;18(3):295-302. doi: 10.1177/1740774520980052. Epub 2021 Apr 5.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Interim analyses and stopping rules in cancer clinical trials.癌症临床试验中的期中分析与终止规则。
Br J Cancer. 1993 Dec;68(6):1179-85. doi: 10.1038/bjc.1993.500.
8
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA five-stage study, including a workshop.RCT 样本量计算中目标差值指定的实用帮助:DELTA 五阶段研究,包括研讨会。
Health Technol Assess. 2019 Oct;23(60):1-88. doi: 10.3310/hta23600.
9
Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.用于将多种实验性治疗与对照进行比较的探索性临床试验的贝叶斯样本量。
Stat Med. 2015 May 30;34(12):2048-61. doi: 10.1002/sim.6469. Epub 2015 Mar 12.
10
A Bayesian-frequentist two-stage single-arm phase II clinical trial design.贝叶斯-频率派两阶段单臂二期临床试验设计。
Stat Med. 2012 Aug 30;31(19):2055-67. doi: 10.1002/sim.5330. Epub 2012 Mar 13.

引用本文的文献

1
Effectiveness of herbal oral care products in reducing dental plaque and gingivitis: an overview of systematic reviews.草药口腔护理产品在减少牙菌斑和牙龈炎方面的功效:系统评价综述。
Can J Dent Hyg. 2024 Jun 1;58(2):120-134. eCollection 2024 Jun.
2
A 680,000-person megastudy of nudges to encourage vaccination in pharmacies.一项涉及 68 万人的大型研究,旨在通过在药店使用助推策略来鼓励接种疫苗。
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6). doi: 10.1073/pnas.2115126119.
3
Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs.评估 2019 年冠状病毒病(COVID-19)药物的不精确试验的统计决策特性。
Value Health. 2021 May;24(5):641-647. doi: 10.1016/j.jval.2020.11.019. Epub 2021 Mar 9.
4
Addressing partial identification in climate modeling and policy analysis.解决气候建模和政策分析中的部分识别问题。
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15). doi: 10.1073/pnas.2022886118.
5
Understanding and misunderstanding randomized controlled trials.理解与误解随机对照试验。
Soc Sci Med. 2018 Aug;210:2-21. doi: 10.1016/j.socscimed.2017.12.005. Epub 2017 Dec 25.

本文引用的文献

1
Why most published research findings are false.为何大多数已发表的研究结果是错误的。
PLoS Med. 2005 Aug;2(8):e124. doi: 10.1371/journal.pmed.0020124. Epub 2005 Aug 30.
2
The ethics of the placebo in clinical practice.临床实践中安慰剂的伦理学问题。
J Med Ethics. 2004 Dec;30(6):551-4. doi: 10.1136/jme.2002.002832.
3
The continuing unethical conduct of underpowered clinical trials.临床试验样本量不足这种持续存在的不道德行为。
JAMA. 2002 Jul 17;288(3):358-62. doi: 10.1001/jama.288.3.358.
4
Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.安慰剂无效吗?一项比较安慰剂与不治疗的临床试验分析。
N Engl J Med. 2001 May 24;344(21):1594-602. doi: 10.1056/NEJM200105243442106.
5
Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research.应对医疗成本效益分析中的不确定性:预期效用最大化对敏感性分析方法的影响以及利用成本效益分析为医学研究设定优先事项
J Health Econ. 2001 Jan;20(1):109-29. doi: 10.1016/s0167-6296(00)00071-0.
6
ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.国际人用药品注册技术协调会三方协调指南。临床试验的统计原则。国际人用药品注册技术协调会E9专家工作组。
Stat Med. 1999 Aug 15;18(15):1905-42.
7
An economic approach to clinical trial design and research priority-setting.一种用于临床试验设计和研究优先级设定的经济学方法。
Health Econ. 1996 Nov-Dec;5(6):513-24. doi: 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9.
8
Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.男性高血压的单药治疗。六种抗高血压药物与安慰剂的比较。退伍军人事务部抗高血压药物合作研究组。
N Engl J Med. 1993 Apr 1;328(13):914-21. doi: 10.1056/NEJM199304013281303.
9
Statistics and ethics in medical research: III How large a sample?医学研究中的统计学与伦理学:III样本量应为多大?
Br Med J. 1980 Nov 15;281(6251):1336-8. doi: 10.1136/bmj.281.6251.1336.